Science & Enterprise subscription

Follow us on Twitter

  • Another way to connect 100 million people end-to-end with Covid-19 vaccines. https://t.co/wIWk0XNDhv
    about 14 hours ago
  • New post on Science and Enterprise: Celebrating the New Administration https://t.co/5ErPGhVDEN #Science #Business
    about 21 hours ago
  • A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its se… https://t.co/2QgwrBLIQd
    about 2 days ago
  • New post on Science and Enterprise: Crispr Heart Disease Biotech Raises $94M in New Funds https://t.co/XJHC82ALY3 #Science #Business
    about 2 days ago
  • A vaccine protecting against multiple Covid-19 viral variations is in development, with an early-stage clinical tri… https://t.co/ZkSq0jOpmg
    about 2 days ago

Please share Science & Enterprise

Covid-19 Vaccines, Therapies – 27 July 2020

Covid-19 vaccine and therapy tracker

BioRender Covid-19 vaccine and therapy tracker. (BioRender.com)

27 July 2020. A regular Monday feature each week on Science & Enterprise is an update on Covid-19 therapies and vaccines in development. The report is provided by BioRender, in Toronto, Ontario, a company offering illustration and graphics tools for life sciences, biotechnology, and other disciplines.

This week’s chart shows since last Monday more new activity for therapies than vaccines, with 15 new Covid-19 therapies joining the array of treatments in development. Of the 337 total therapies, 252 of these treatments are in clinical trials, a gain of 16 since last Monday. Also since last Monday, one more new candidate joined the Covid-19 vaccine collection raising the total to 156. Of that number, 34 vaccine candidates are in clinical trials, a gain of three since last week.

In addition to the summary dashboard shown above, the BioRender Covid-19 vaccine and therapy page provides details of the vaccines and therapies, as well as an activity feed showing news updates on these drugs.

A story in this morning’s New York Times reminds us that not all antibodies produced by Covid-19 vaccines, or the tests that detect them, are alike. The most potent neutralizing antibodies are those that block proteins on the SARS-CoV-2 coronavirus spike from infecting cells, while other antibodies bind to the virus without neutralizing it. Early-stage clinical trials look primarily for safety issues with vaccines, but also for the candidate’s ability to produce an immune response. As vaccines progress into later stage trials, we will watch for candidates’ performance in producing these more potent antibodies.

More from Science & Enterprise:

*     *     *

2 comments to Covid-19 Vaccines, Therapies – 27 July 2020